Ipilimumab

Ipilimumab (Yervoy) is an antibody inhibitor that blocks the inhibitory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells, with immune-activating properties. Used for the treatment of unresectable or metastatic melanoma, this antibody exhibits antitumor activity.

Methods: In a co-culture system of Jurkat T cells expressing CTLA-4 and Raji B cells, anti-CD3 antibody and gradient concentrations of Ipilimumab (0–100 μg/mL) were added, and luciferase activity driven by the IL-2 promoter was detected after 4 hours of incubation.
Results: Ipilimumab concentration-dependently enhanced luciferase expression (up to approximately 3-fold), and replacing with Raji cells highly expressing CD80/CD86 eliminated the early inhibitory effect produced by low concentrations of Ipilimumab. [1]

Methods: In an hCTLA-4 transgenic mouse MC-38 subcutaneous xenograft tumor model, Ipilimumab was administered by intraperitoneal injection at a dose of 10 mg/kg, twice weekly for 3 consecutive weeks (control group received PBS).
Results: The Ipilimumab treatment group showed complete tumor regression in 2 out of 7 mice, comparable to the efficacy of pro-Ipilimumab, confirming its antitumor activity. [2]

Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. Concentrations: 0, 0.5, 5.0, and 50 μg/mL. Incubation Time: 10-14 days. Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt's lymphoma cell line (Daudi).

Objective: To investigate whether Ipilimumab and PD-1 antibody enhance the ability of T cells to control the outgrowth of EBV-induced lymphomas. Formulation: PBS. Dosages: 100 μg, three times weekly

Human

Monoclonal

Unconjugated